U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. Science and Research Special Topics
  4. Advancing Regulatory Science
  5. Cost Barriers to HIV pre-exposure prophylaxis (PrEP) Retention in Care in US Populations - 12/03/2020 - 12/03/2020
  1. Advancing Regulatory Science

Webcast | Virtual

Event Title
Cost Barriers to HIV pre-exposure prophylaxis (PrEP) Retention in Care in US Populations
December 3, 2020

Date:
December 3, 2020

Johns Hopkins University CERSI

Thursday, December 3, 2020

Presented By

Picture of Lorraine Dean, ScD

Lorraine Dean, ScD
Assistant Professor,
Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health

About the Presentation

HIV pre-exposure prophylaxis (PrEP), a formulation of TDF/FTC also referred to as Truvada or Descovy, has recently been approved for use in generic form. When used correctly, PrEP is over 99% effective in reducing HIV transmission; however, barriers remain to optimal uptake and retention. Cost has been cited as a barrier to use of these medications, and issues of cost become of greater interest in light of a new potentially lower-cost generic PrEP option. This presentation discussed PrEP costs as a barrier, and reported on two preliminary analyses. The first introduced a novel PrEP retention metric of the rate at which patients failed to pick up PrEP at the pharmacy point-of-sale, and the second used a unique discrete choice experiment to examine how patients made trade-offs between PrEP’s cost, side effects, and mode of transmission.

About the Presenter

Dr. Dean has been Assistant Professor in Epidemiology at Johns Hopkins Bloomberg School of Public Health since January 2016, after being Instructor at the University of Pennsylvania Perelman School of Medicine since 2013. Her current work focuses on social and economic determinants of disparities in cancer and HIV. She has led several studies in this area as PI of an NIH K01, NIAID R21, NINR R21, NIHF31 and Center for AIDS Research grants. She holds a doctorate in Social Epidemiology from Harvard School of Public Health. Her early career opportunities as an undergraduate at Penn, which she completed in 2003 as a first-generation under-represented minority college student, paved the way to a year in Venezuela conducting breast cancer research under the William J. Fulbright Program. Prior to her time on faculty, she coordinated over $14 million of activities in both state- and federally-funded tobacco control initiatives in Philadelphia which led to a reduction in smoking for 25,000 residents. Thus, her research is inspired by building the evidence-based on which policies are made for those at risk chronic disease survivors.

Recording

https://collaboration.fda.gov/pc9lkzjw3tdl/

Back to Top